A nomogram to predict disease-free survival in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy based on clinicopathological and sonographic features | Synapse
March 3, 2026Open Access
A nomogram to predict disease-free survival in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy based on clinicopathological and sonographic features
Key Points
Poor survival outcomes predicted using a newly developed nomogram model for triple-negative breast cancer patients.
The nomogram incorporates clinicopathological and sonographic features to enhance prediction accuracy.
Observational analysis evaluated data from patients with residual lesions after neoadjuvant chemotherapy for accuracy.
Findings highlight potential for the nomogram to guide treatment strategies in high-risk breast cancer populations.
Abstract
Our study developed a nomogram model to predict poor survival outcomes in TNBC patients with residual lesions after NAC, which may provide guidance for treatment strategies in high-risk populations.